ClinicalTrials.gg
CompletedNCT06391437Updated Apr 30, 2024

Prevalence Of Vitamin A Deficiency In Critically Ill Children With Sepsis And Its Association With Clinical Outcomes

An observational study in Vitamin A Deficiency in Children, sponsored by Benha University. Completed at 1 site in Egypt. Open to participants aged 1 Month to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by Benha University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
220
Ages
1 Month to 16 Years
Sex
All
01

Study summary

Aim of the work is to assess the prevalence of vitamin A deficiency in critically ill children with sepsis and the association between vitamin A deficiency and clinical outcomes

Read the detailed description

Vitamin A plays an essential role in a large number of physiological functions that encompass vision, growth, reproduction, hematopoiesis, and immunity.

Despite major advances in the knowledge of vitamin A biology, its deficiency is still a serious public health problem that affects an estimated 127 million preschool children. In children, vitamin A deficiency results in increased risks of mortality and morbidity from infections, blindness and anemia. Many of these effects can be linked to the immunological functions of vitamin A.

Vitamin A modulates immunity through its active metabolite retinoic acid (RA), which acts on retinoid receptors in various cell types. Studies utilizing various animal models of vitamin A or retinoid receptor deficiency have revealed an integral role for RA in immunity and tolerance.

Retinoic acid (RA) has been reported to promote anti-inflammatory regulatory T cell (Treg) differentiation and inhibit interleukin (IL)-6-induced proinflammatory T helper 17 (Th17) cells, which could balance pro- and anti-inflammatory immunity.

Vitamin A deficiency (VAD ) is associated with adverse health outcomes due to an increased risk of infection in children. VAD could impact immunity at multiple levels, including disturbing the integrity of the gastrointestinal mucosal barrier, decreasing monocyte and natural killer (NK) cell numbers, and impairing the function of macrophages, dendritic cells, and neutrophils.

Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response to infection, contributes to millions of deaths worldwide each year, with a mortality rate of more than 25%. Remarkably, sepsis is a common cause of death in children. The mortality of severe sepsis was reported to be as high as 34.6% in children.

As a public health problem, sepsis has posed a significant burden on extensive health care resources for many years. It is reported as a complicated immune disorder characterized by both a hyperinflammatory immune response in the early stage and immunosuppression in the later stage.

Most deaths from sepsis occur due to opportunistic pathogen superinfections or latent viral reactivation resulting from immunosuppression.

VA is an immunomodulatory, and its deficiency may cause an imbalance between pro- and anti-inflammatory factors and impaired immune function, which are found in sepsis. There is a biological rationale that VAD may be a contributing factor related to poor clinical outcomes in patients with sepsis. Importantly, VAD is highly prevalent in children, especially in preschool children. However, there is limited data regarding the correlation between VAD and sepsis, so we hypothesize that VAD may play an important role in the pathogenesis and progression of sepsis in children.

02

Conditions studied

  • Vitamin A Deficiency in Children

Browse trials for

03

In context

Vitamin A Deficiency

67 studies on the registry are indexed under Vitamin A Deficiency; 7 are open to participants now.

This study's enrollment of 220 is below the median of 258 across 17 observational studies indexed under Vitamin A Deficiency.

Browse Vitamin A Deficiency studies →

Lead sponsor

Benha University is the lead sponsor of 362 studies on the registry; 66 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This is a prospective study will be conducted from May 2023 to October 2023 in pediatric intensive care unit (PICU) at Benha university Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All pediatric Patients from 29 days to 16 years old who were admitted to the pediatric intensive care unit (PICU) with sepsis as defined by International pediatric sepsis consensus conference will be consecutively recruited in this study.

Sex- and age-matched approximate-health children without sepsis will be recruited as a control group.

Exclusion criteria

Exclusion Criteria:

    • Age > 16 years old.
    • Premature infants and low birth weight infants.
    • Children with underlying organ dysfunction, having received chemotherapy or radiotherapy, hematological , primary or acquired immunodeficiency.
    • Children who discharged against medical advice with an uncertain prognosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
220 participants (actual)
Patient registry
No

Groups and cohorts

  • Control group

    Sex- and age-matched approximate-health children without sepsis will be recruited as a control group.

    Diagnostic Test: Extraction of blood sample

  • Studied group

    All pediatric Patients from 29 days to 16 years old who were admitted to the pediatric intensive care unit (PICU) with sepsis as defined by International pediatric sepsis consensus conference will be consecutively recruited in this study.

    Diagnostic Test: Extraction of blood sample

Interventions

  • Diagnostic testExtraction of blood sample

    Blood samples will be collected from all patients during the first 24 h of admission before enteral nutrition and/ or parenteral nutrition.

06

What researchers measure

Primary outcomes

  1. Severity of sepsis in pediatric patients with vitamin A deficiency

    Severity of sepsis in pediatric patients with vitamin A deficiency

    Time frame: 1 month

  2. Clinical outcomes in septic pediatric patients with vitamin A deficiency

    Length of hospital stay and mortality rate in pediatric patients with vitamin A deficiency

    Time frame: 1 month

07

Study locations

1 site
  • Benha University Hospital
    Cairo, 13511, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Mar 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2024
First posted
Apr 30, 2024
StartActual
May 1, 2023
Primary completionActual
Mar 1, 2024
CompletionActual
Mar 31, 2024
Last update
Apr 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06391437
Lead sponsor
Benha University
Responsible party
Amany Mohammed El-Rebigi, MD (Lecturer of Pediatric and Neonatology, Benha University) — Principal investigator
First posted
Apr 30, 2024
Start date
May 1, 2023
Primary completion
Mar 1, 2024
Completion
Mar 31, 2024
Last update
Apr 30, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion